Xencor (XNCR) Operating Income (2013 - 2026)
Xencor (XNCR) posted quarterly Operating Income of -$77.9 million for Q1 2026, down 80.31% year-over-year from -$395.4 million in Q1 2025, and down 45.19% quarter-over-quarter from -$53.6 million in Q4 2025.
Xencor (XNCR) Operating Income (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Operating Income for 14 consecutive years, with -$77.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 80.31% year-over-year to -$77.9 million; the TTM figure through Mar 2026 stood at -$212.2 million (down 27.11% YoY), while the FY2025 annual figure was -$177.5 million, up 0.51% from the prior year.
- Operating Income eased to -$77.9 million in Q1 2026 per XNCR's latest filing, from -$53.6 million in the prior quarter.
- Across five years, Operating Income topped out at $26.5 million in Q1 2022 and bottomed at -$77.9 million in Q1 2026.
- Historically, Operating Income has averaged -$38.2 million across 5 years, with a median of -$42.6 million in 2022.
- On a YoY basis, Operating Income climbed as much as 268.87% in 2022 and fell as far as 408.13% in 2022.
- Xencor's Operating Income stood at -$42.6 million in 2022, then jumped by 35.79% to -$27.4 million in 2023, then surged by 51.82% to -$13.2 million in 2024, then plunged by 306.95% to -$53.6 million in 2025, then sank by 45.19% to -$77.9 million in 2026.
- Business Quant data shows XNCR's Operating Income at -$77.9 million in Q1 2026, -$53.6 million in Q4 2025, and -$47.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -37.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.07 Mn |
| Mar 31, 2026 | -77.86 Mn |
| Dec 31, 2025 | -53.63 Mn |
| Sep 30, 2025 | -47.52 Mn |
| Jun 30, 2025 | -33.17 Mn |
| Mar 31, 2025 | -43.18 Mn |
| Dec 31, 2024 | -13.18 Mn |
| Sep 30, 2024 | -55.20 Mn |
| Jun 30, 2024 | -55.37 Mn |
| Mar 31, 2024 | -54.66 Mn |
| Dec 31, 2023 | -27.35 Mn |
| Sep 30, 2023 | -18.27 Mn |
| Jun 30, 2023 | -26.00 Mn |
| Mar 31, 2023 | -60.74 Mn |
| Dec 31, 2022 | -42.59 Mn |
| Sep 30, 2022 | -38.35 Mn |
| Jun 30, 2022 | -28.00 Mn |
| Mar 31, 2022 | 26.47 Mn |
| Dec 31, 2021 | 91.65 Mn |
| Sep 30, 2021 | -41.30 Mn |